| Date | Session | Speaker | Topic | 
                
                  | 
 October 15th
 | 
 Openning Lecture
 | 
 Wojciech Zareba
 | 
 Drug-Induce QT prolongation - talk
 | 
                
                  |  |  | Wojciech Zareba | Drug-Induced QT prolongation - Manuscript | 
                
                  |  | Mechanisms | Charles Antzelevitch | Drug-Induced Spatial Dispersion of Repolarization | 
                
                  |  | Methods | Paul Kligfield | ECG Measurement of QT Interval | 
                
                  |  | Clinical Aspects | Arthur Moss | Long QT Syndrome as Paradigm for Drug-Induced QT Prolongation | 
                
                  |  | Drug Testing | William Wheeler | Drug-Induced Torsade de Pointes: Regulatory Evolution | 
                
                  | 
 October 16th
 | 
 Mechanisms
 | 
 Nabil El-Sherif
 | 
 Mechanism of Drug-Induced TdP
 | 
                
                  |  | Methods | Ilan Goldenberg | How to Measure QT | 
                
                  |  | Clinical Aspects | James Daubert | Managing the Safety of Drugs for Atrial Fibrillation | 
                
                  |  | Drug Testing | Fabio Badilini | QT Measurements On-screen Methods | 
                
                  | 
 October 17th
 | 
 Mechanisms
 | 
 Dan Roden
 | 
 Pharmacogenomics of Drug-Induced Conditions
 | 
                
                  |  | Methods | Pentti Rautaharju | Is QT Prolonged or Shortened? Normal Limits. | 
                
                  |  | Clinical Aspects | Wojciech Zareba | Antipsychotic Drugs and Risk of TdP | 
                
                  |  | Drug Testing | Jean Philippe Couderc | Beyond QT Prolongation in Drug Studies | 
                
                  | 
 October 18th
 | 
 Mechanisms
 | 
 Michael Sanguinetti
 | 
 hERG Channel Function in LQT2 and Drug Induced Conditions
 | 
                
                  |  | Methods | Marek Malik | Heart Rate Correction of the QT interval | 
                
                  |  | Clinical Aspects | Richard Kovacs | Antibiotics and Acquired Long QT Syndrome: Advice for the    Prescriber. | 
                
                  |  | Drug Testing | Borje Darpo | What QT prolongation is of concern? | 
                
                  | 
 October 19th
 | 
 Mechanisms
 | 
 Terry Campbell
 | 
 Predicting Drug-HERG Interactions
 | 
                
                  |  | Methods | Emanuela Locati | QT Interval Dynamics | 
                
                  |  | Clinical Aspects | Luiz Belardinelli | Not All QT-prolonging Drugs are Torsadogenics | 
                
                  |  | Drug Testing | Dirhaj Narula | ECG Core Laboratory Approach to Drug testing | 
                
                  | 
 October 20th
 | 
 Mechanisms
 | 
 Silvia Priori
 | 
 Ion channel Genes and Propensity to TdP
 | 
                
                  |  | Methods | Pierre Maison Blanche | RR Bin Approach for QT analyses | 
                
                  |  | Clinical Aspects | Mark Haigney | QT Variability and its Application for Drug Testing | 
                
                  |  | Drug Testing | William Wheeelr | Assessing QT Liability in Oncology Drug Development | 
                
                  | 
 October 21th
 | 
 Mechanisms
 | 
 Michael Ackerman
 | 
 Pharmacogenetics of Drug-Induced Sudden Cardiac Arrest
 | 
                
                  |  | Methods | Antony Fossa | ECG Restitution and its Relevance for Drug-Induced    Repolarization Abnormalities | 
                
                  |  | Clinical Aspects | Ihor Gussak | Short QT Interval and Drugs | 
                
                  |  | Drug Testing | Irina Salivieva | Pacing in Drug Testing | 
                
                  | 
 October 22th
 | 
 Clinical Aspects
 | 
 Li Zhang
 | 
 Case Demonstrations in Congenital and Acquired Long QT Syndrome. Can You Make A Correct ECG Interpretation?
 | 
                
                  |  | Methods | Stefan Kaab | Drug-induced LQT-Syndrome: Sotalol-Experience, Heart failure, Susceptibility to drug induced LQT | 
                
                  |  | Methods | Andrés Pérez Riera | Relationship Among Amiodarone, New Class III Antiarrhytmics, Miscellaneous Agents and Acquired Long QT Syndrome | 
                
                
                  | 
 October 23th - 31th
 | 
 Discussion
 |  |  |